Dr. Doug Mahoney

In the Cumming School of Medicine's Charbonneau Cancer Center and Alberta Children's Hospital Research Institute, Dr. Douglas Mahoney works as a translational scientist. He has made significant contributions over the past 15 years to the development of numerous cancer immunotherapies that are currently being explored in human clinical trials. In order to create ""designed viruses"" that elicit anticancer immunity and enhance Chimeric Antigen Receptor (CAR) T-cell treatment of cancer, his lab is currently concentrating on understanding how rhabdoviruses interact with immune cells. His lab collaborates with top genomics and immunology labs in Alberta and uses cutting-edge synthetic biology, high-resolution in vivo imaging, and robotic screening technologies, among other approaches. A brand-new research programme named ACTION (Alberta Cellular Therapy and Immune Oncology), which was established in collaboration with the Canadian Cancer Society in 2020, has Dr. Mahoney as its Scientific Director. Doug's team at ACTION is working to create revolutionary next-generation tailored T cell treatments against fresh targets found on solid tumours with a high mortality rate.

Qualification

• MD
• PhD